Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin’s lymphoma in three randomised EORTC trials
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference15 articles.
1. The achievements of the EORTC Lymphoma Group;Raemaekers;Eur J Cancer,2002
2. Superiority of second over first generation chemotherapy in a randomised trial for stage III–IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980–1985 EORTC trial. The EORTC Lymphoma Group;Carde;Ann Oncol,1991
3. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma;Somers;Ann Oncol,1994
4. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III–IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group;Meerwaldt;Ann Oncol,1997
5. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomised phase III EORTC study;Kluin-Nelemans;J Natl Cancer Inst.,2001
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A unique research infrastructure from the European Organisation for Research and Treatment of Cancer (EORTC) to optimize long-term follow up of patients-the YOU (Your Outcome Update) protocol: Rationale, scope, design and research opportunities;Journal of Cancer Policy;2018-05
2. Accelerated partial breast irradiation: The need for well-defined patient selection criteria, improved volume definitions, close follow-up and discussion of salvage treatment;The Breast;2012-12
3. Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma;European Journal of Nuclear Medicine and Molecular Imaging;2008-04-02
4. Strategies for Improving Outcomes with 14-Day Anthracycline- Based Regimens in Patients with Aggressive Lymphomas;Clinical Lymphoma and Myeloma;2007-12
5. PET and PET/CT for response evaluation in lymphoma: Current practice and developments;Leukemia & Lymphoma;2007-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3